Skip to content

Vascular Effects of Triglyceride-rich Lipoproteins

Unravelling the Mechanisms of Vascular Protection by n3-PUFAs to Optimise and Support Their Use as Bioactives by the Food Industry

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01618071
Enrollment
16
Registered
2012-06-13
Start date
2012-06-30
Completion date
2012-10-31
Last updated
2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipemia, Nitric Oxide, Postprandial Period, Vascular Resistance, Vasodilation

Keywords

n-3 PUFA, Endothelial cells, Nitric oxide, Oxidative stress, Blood pressure, Vasodilation, Lipemia, Unsaturated dietary fats

Brief summary

Many types of cardiovascular disease begin when the layer of cells lining blood vessels (endothelial cells) start to function abnormally. This causes white blood cells (monocytes) to enter the blood vessel wall and eventually form lesions. Fats from foods we consume are carried in the blood for 3-8 hours after a fatty meal in small particles known as chylomicrons (CM) and chylomicron remnants (CMR). The overall aim of this project is to investigate the idea that n-3 polyunsaturated fatty acids (PUFA) protect against heart disease by modifying the effect of CMR on endothelial cells and monocytes. We hypothesize that n3-PUFA carried in CMR reduce detrimental events which promote blood vessel damage and activate protective mechanisms to improve the function of arteries.

Interventions

DIETARY_SUPPLEMENTHigh-fat meals varying in their fatty acid composition

70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements

Sponsors

Royal Veterinary College
CollaboratorUNKNOWN
King's College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
35 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy males * Non-smokers * Aged 35-70 years * Fasting TAG concentrations ≥1.2 mmol/L.

Exclusion criteria

* Reported history of CVD (myocardial infarction, angina, venous thrombosis, stroke), impaired fasting glucose/uncontrolled type 2 diabetes (or fasting glucose ≥ 6.1 mmol/L), cancer, kidney, liver or bowel disease. * Presence of gastrointestinal disorder or use of drug, which is likely to alter gastrointestinal motility or nutrient absorption. * History of substance abuse or alcoholism (previous weekly alcohol intake \>60 units/men) * Current self-reported weekly alcohol intake exceeding 28 units * Allergy or intolerance to any component of test meals * Unwilling to restrict consumption of any source of fish oil for the length of the study * Weight change of \>3kg in preceding 2 months * Body Mass Index \<20 and \>35 kg/m2 * Fasting blood cholesterol \> 7.8 mmol/L * Current cigarette smoker. * Current use of lipid lowering medication

Design outcomes

Primary

MeasureTime frameDescription
Activation of inflammatory/oxidative stress pathways within cultured endothelial cells following treatment with 6 h postprandial chylomicron remnant-rich lipoprotein fraction6 h post-mealThe primary outcome of the study is activation of inflammatory/oxidative stress pathways within cultured endothelial cells following incubation with pooled postprandial lipoprotein fractions rich in chylomicron remnants. Due to the nature of this type of research this necessitates more than one primary outcome measure: the primary measures are NF-kappa-beta activation, cytokine production (e.g. interleukin-6) and reactive oxygen species generation in the cultured human endothelial cells.

Secondary

MeasureTime frame
Incremental area under the plasma concentration versus time curve (iAUC) of glucose0, 1, 2, 3, 4, 5 and 6 h post-meal
Incremental area under the plasma concentration versus time curve (iAUC) for non-esterified fatty acids0, 1, 2, 3, 4, 5 and 6 h post-meal
Incremental area under the plasma concentration versus time curve (iAUC) for plasma fatty acid composition (%)0, 1, 2, 3, 4, 5 and 6 h post-meal
Incremental area under the plasma concentration versus time curve (iAUC) for cholesterol0, 1, 2, 3, 4, 5 and 6 h post-meal
Incremental area under the unit measure versus time curve for brachial augmentation index0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min post-meal
Incremental area under the unit measure versus time curve for systolic blood pressure0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min post-meal
Incremental area under the plasma concentration versus time curve (iAUC) of triacylglycerol0, 1, 2, 3, 4, 5 and 6 h post-meal
Change in digital volume pulse stiffness index0, 2, 4 and 6 h post-meal
Change in digital volume pulse reflection index0, 2, 4 and 6 h post-meal
Change in plasma nitrite/nitrate concentrations0, 2, 4 and 6 h
Change in plasma 8-isoprostane F2alpha concentrations0, 2, 4 and 6 h post-meal
Activation of inflammatory/oxidative stress pathways within cultured endothelial cells following treatment with 4 h postprandial chylomicron remnant-rich lipoprotein fraction4 h post-meal
Activation of inflammatory/oxidative stress pathways within cultured endothelial cells following treatment with 5 h postprandial chylomicron remnant-rich lipoprotein fraction5 h post-meal
Incremental area under the unit measure versus time curve for diastolic blood pressure0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min post-meal

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026